<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131218</url>
  </required_header>
  <id_info>
    <org_study_id>PK and PD of Sug</org_study_id>
    <nct_id>NCT04131218</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Anesthesia Obese Patients Undergoing Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to illustrate pharmacokinetics and pharmacodynamics of
      sugammadex in reversal of vecuronium-induced neuromuscular blockade in anesthesia obese
      patients undergoing bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 obese patients undergoing bariatric surgery were divided into 2 groups according to body
      mass index (BMI), including obese group (O group, n=8, 25≤BMI≤39.9kg/m²) and morbidly obese
      group (M group, n=8, BMI≥40kg/m²).

      Vecuronium was continuous infusing to maintain moderate neuromuscular blockade during the
      laparoscopic surgery and stopped infusing after the laparoscopic procedure. A single dose
      administration of sugammadex (Sug) 2.0mg/kg according to ideal body weight (IBW) was given at
      the reappearance of the second twitch of the train-of-four (TOF) response.

      On one hand, venous blood samples were obtained before administration of Sug and at 2, 3, 5,
      10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours after administration of Sug to determine
      plasma concentration of Sug using HPLC-MS. On the other hand, time from start of
      administration of Sug to recovery of TOF ratio to 0.9 and other clinical indicators were also
      recorded.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of Sugammadex</measure>
    <time_frame>0, 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours</time_frame>
    <description>venous blood samples were obtained</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery Time and TOF ratio</measure>
    <time_frame>TOF ratio at 30, 60, 90, 120, 150 seconds after administration</time_frame>
    <description>time from start of administration of Sug to recovery of TOF ratio to 0.9 and other indicators</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8, 25≤BMI≤39.9kg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morbidly obese group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8, BMI≥40kg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).</description>
    <arm_group_label>Morbidly obese group</arm_group_label>
    <arm_group_label>Obese group</arm_group_label>
    <other_name>Bridion</other_name>
    <other_name>Org 25969</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA: Ⅰ~Ⅲ

          -  BMI≥25kg/m²

          -  Patients receiving bariatric surgery.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Neuromuscular diseases

          -  Malignant hyperthermia or allergic history during general anesthesia

          -  Drugs that react with rocuronium and vecuronium were taken
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Ärnlöv J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Fürst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362. Epub 2017 Jun 12.</citation>
    <PMID>28604169</PMID>
  </reference>
  <reference>
    <citation>Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000. Review.</citation>
    <PMID>20067334</PMID>
  </reference>
  <reference>
    <citation>Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007 Feb;106(2):283-8.</citation>
    <PMID>17264722</PMID>
  </reference>
  <reference>
    <citation>Sanfilippo M, Alessandri F, Wefki Abdelgawwad Shousha AA, Sabba A, Cutolo A. Sugammadex and ideal body weight in bariatric surgery. Anesthesiol Res Pract. 2013;2013:389782. doi: 10.1155/2013/389782. Epub 2013 Jun 6.</citation>
    <PMID>23840203</PMID>
  </reference>
  <reference>
    <citation>Asztalos L, Szabó-Maák Z, Gajdos A, Nemes R, Pongrácz A, Lengyel S, Fülesdi B, Tassonyi E. Reversal of Vecuronium-induced Neuromuscular Blockade with Low-dose Sugammadex at Train-of-four Count of Four: A Randomized Controlled Trial. Anesthesiology. 2017 Sep;127(3):441-449. doi: 10.1097/ALN.0000000000001744.</citation>
    <PMID>28640017</PMID>
  </reference>
  <reference>
    <citation>Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, Hunter JM. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010 Jan;104(1):31-9. doi: 10.1093/bja/aep340.</citation>
    <PMID>20007792</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Sugammadex</keyword>
  <keyword>Obese</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

